We are live on ! Find out more
VKTX icon

Viking Therapeutics

134 hedge funds and large institutions have $238M invested in Viking Therapeutics in 2021 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 40 increasing their positions, 47 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

476% more call options, than puts

Call options by funds: $8.98M | Put options by funds: $1.56M

5% more capital invested

Capital invested by funds: $227M → $238M (+$11M)

0.19% less ownership

Funds ownership: 48.49%48.3% (-0.19%)

3% less funds holding

Funds holding: 138134 (-4)

15% less repeat investments, than reductions

Existing positions increased: 40 | Existing positions reduced: 47

25% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 12

Holders
134
Holders Change
-4
Holders Change %
-2.9%
% of All Funds
2.35%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
9
Increased
40
Reduced
47
Closed
12
Calls
$8.98M
Puts
$1.56M
Net Calls
+$7.42M
Net Calls Change
+$1.98M
Name Holding Trade Value Shares
Change
Change in
Stake
Susquehanna International Group
26
Susquehanna International Group
Pennsylvania
$1.2M -$392K -63,393 -25%
RJFSA
27
Raymond James Financial Services Advisors
Florida
$1.14M +$117K +18,860 +12%
Charles Schwab
28
Charles Schwab
California
$1.08M +$3.44K +556 +0.3%
Swiss National Bank
29
Swiss National Bank
Switzerland
$975K +$62.4K +10,100 +7%
William Blair & Company
30
William Blair & Company
Illinois
$912K -$71.4K -11,555 -7%
Goldman Sachs
31
Goldman Sachs
New York
$883K -$935K -151,370 -52%
ERSOT
32
Employees Retirement System of Texas
Texas
$872K
Bank of Montreal
33
Bank of Montreal
Ontario, Canada
$849K -$105K -17,065 -12%
Rafferty Asset Management
34
Rafferty Asset Management
New York
$825K -$334K -54,032 -29%
Citadel Advisors
35
Citadel Advisors
Florida
$779K -$366K -59,285 -32%
CC
36
Cornerstone Capital
California
$768K -$76.6K -12,400 -9%
Wells Fargo
37
Wells Fargo
California
$716K -$83.7K -13,553 -11%
UBS AM
38
UBS AM
Illinois
$698K -$112K -18,069 -14%
RhumbLine Advisers
39
RhumbLine Advisers
Massachusetts
$688K +$20.9K +3,378 +3%
PP
40
PDT Partners
New York
$653K -$206K -33,300 -24%
First Trust Advisors
41
First Trust Advisors
Illinois
$621K +$611K +98,936 New
SG Americas Securities
42
SG Americas Securities
New York
$615K +$531K +85,882 +708%
AA
43
ALPS Advisors
Colorado
$602K -$43.4K -7,030 -7%
Citigroup
44
Citigroup
New York
$591K -$1.21M -195,071 -67%
California State Teachers Retirement System (CalSTRS)
45
California State Teachers Retirement System (CalSTRS)
California
$591K -$2.37K -383 -0.4%
State of Wisconsin Investment Board
46
State of Wisconsin Investment Board
Wisconsin
$559K
Osaic Holdings
47
Osaic Holdings
Arizona
$502K +$13.6K +2,200 +3%
AllianceBernstein
48
AllianceBernstein
Tennessee
$499K
Group One Trading
49
Group One Trading
Illinois
$457K +$59.3K +9,599 +15%
HF
50
HRT Financial
New York
$444K +$311K +50,271 +245%

VKTX Hedge Fund Activity: Q3 2021 in Review

134 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Viking Therapeutics (VKTX) for Q3 2021, worth a combined $238M — up 4.9% from $227M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of VKTX and 9 opened new positions — a net loss of 3 holders — while 47 trimmed existing stakes and 40 added.

The largest buyer was Nuveen, adding an estimated $5.13M. The largest seller was State Street, cutting an estimated $5.83M.

  • 134 institutional investors held Viking Therapeutics (VKTX) as of Q3 2021, down from 138 in Q2 2021.
  • Funds reported $238M of Viking Therapeutics stock for Q3 2021, up 4.9% quarter-over-quarter.
  • 9 funds opened new Viking Therapeutics positions in Q3 2021 and 12 closed out, a net change of -3 holders.
  • The largest Viking Therapeutics buyer in Q3 2021 was Nuveen, an estimated $5.13M added.
  • The largest Viking Therapeutics seller in Q3 2021 was State Street, an estimated $5.83M sold.

Based on aggregated 13F filings for Q3 2021.